Angiotensin II receptor antagonist and combinations Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY HAVE BARCODES.

This form may be faxed to 844-403-1029.

Member Information (required)			Provider Information (required)					
Member Name:			Provider Name:					
Insurance ID#:			NPI#:	NPI#: Specialty:				
Date of Birth:			Office Phone	:				
Street Address:			Office Fax:					
City:	State:	ZIP:	Office Street	Address:				
Phone:	I		City:	State:		ZIP:		
Medication Information (required)								
Medication Name:			Strength: Dosage Form:		m:			
			Directions for Use:					
Clinical Information (required)								
1. Select the diagr	nosis below:			(qui cu)				
-	ar risk reduction (Mica	ardis only)						
Heart failure								
Hypertension Hypertensive	n e patient with left ventri	cular hypertrophy (C	ozaar and Hv	zaar only)				
	in Type 2 diabetic pat	••••••	-	zaar omy				
 Post-myocardial infarction (Diovan only) 								
Other diagnosis: ICD-10 Code				10 Code:		_		
2. Has the patient demonstrated a failure or intolerance to a majority (two or more in a class with at least								
two alternatives or one in a class with only one alternative) of the preferred formulary/preferred drug list alternatives for the given diagnosis (e.g., candesartan, eprosartan, irbesartan, losartan, telmisartan,						t		
valsartan, candesartan-HCT, irbesartan-HCT, losartan-HCT, telmisartan-HCT, valsartan-HC								
olmesartan and olmesartan-HCT)?								
If yes, please submit documentation, including medication(s) tried, dates of trial(s) and reason for treatment failure(s):								
3. Does the patient have a documented contraindication to the listed formulary alternatives (e.g.,								
candesartan, eprosartan, irbesartan, losartan, telmisartan, valsartan, candesartan-HCT, irbesartan-HCT, losartan-HCT, telmisartan-HCT, valsartan-HCT, olmesartan and olmesartan-HCT)?								
If yes, please submit documentation, including medication name(s) and contraindication:								
4. Has the patient had an adverse reaction OR would be reasonably expected to have an adverse reaction						n 🛛 Yes 🗆 No		
to a majority (two or more in a class with at least two alternatives or one in a class with only one alternative) of the listed formulary agents used for the requested indication (e.g., candesartan,								
eprosartan, irbesartan, losartan, telmisartan, valsartan, candesartan-HCT, irbesartan-HCT, losartan-								
HCT, telmisartan-HCT, valsartan-HCT, olmesartan and olmesartan-HCT)?								
If yes, please submit documentation, including medication name(s) and adverse reaction(s):					-			
						- 1		

This document – and others if attached – contains information that is privileged, confidential and/or may contain protected health information (PHI). The provider named above is required by applicable law to safeguard PHI. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.** Office use only: ARBs_2019Dec

Angiotensin II receptor antagonist and combinations Prior Authorization Request Form (Page 2 of 2)

 5. Does the patient have a clinical condition for which there is no listed formulary agent to treat the condition based on published guidelines or clinical literature? If yes, please submit documentation, including the clinical condition: 	🗆 Yes 🗖 No	
6. Is the drug being prescribed within the manufacturer's published dosing guidelines or does the dose fall within dosing guidelines found in accepted compendia or current literature (e.g., package insert, AHFS, Micromedex, current accepted guidelines, etc.)?		

Information on this form is accurate as of this date.

Prescriber's Signature:	Date:		

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

<u>Please note</u>: **This request may be denied unless all required information is received.** For more information about the prior authorization process, please contact us at 855-811-2218. Monday – Friday: 8 a.m. to 1 a.m. Eastern, and Saturday: 9 a.m. to 6 p.m. Eastern

This document – and others if attached – contains information that is privileged, confidential and/or may contain protected health information (PHI). The provider named above is required by applicable law to safeguard PHI. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.** Office use only: ARBs_2019Dec